Cue Biopharma Inc. (CUE) Next Earnings Date & Expected ±12.5% Move

Per the Roarable RQD rating, CUE scores 33 out of 100 and receives a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 8/20 (ROIC -35%; FCF yield -14.03%), Whale 13F Flow at 8/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 6/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 8/20 (Altman Z 2.5; Piotroski F 4/9; Debt/Equity 0.5).

For a prospective investor, the pillar profile points to weakness across most categories. Cash generation is negative on both ROIC and free-cash-flow yield, which means the business currently consumes capital rather than producing it. Insider conviction is the lowest-scoring pillar at 3/20, which the rating associates with recent Form 4 and congressional flow clustering. The balance-sheet pillar is only moderately supportive: an Altman Z of 2.5 and a Piotroski F of 4/9 do not indicate strong financial health, though Debt/Equity of 0.5 is a relatively contained leverage figure. The macro pillar reflects a beta of 1.0, meaning the stock is rated as moving in line with the broader market rather than amplifying it. Upside drivers would need to come from a reversal in cash flow or a material change in insider and institutional behavior; the rating does not identify a specific catalyst that would produce that reversal. Valuation tradeoffs cannot be fully assessed because P/E, forward P/E, EV/EBITDA, and EPS are not available in source data.

Cue Biopharma Inc. is a NASDAQ-listed issuer in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry, per the company profile. The profile does not describe its specific products, customers, or revenue model. Per the SEC financials, the company reported revenue of $27.5M for FY 2025, up from $9.3M in FY 2024 and $5.5M in FY 2023, but the source data does not identify the revenue sources. Per the profile, the market capitalization is $0.2B.

Per the market data, operating margin and net margin are each -60%, and gross margin is 0%. ROIC is -35%, and the FCF yield is -14.03%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 4/9, and Debt/Equity is 0.5. Reported operating losses narrowed from $-52.1M in FY 2023 to $-26.6M in FY 2025, while cash reported for FY 2025 is $27.1M. Debt is reported as $0.0M for FY 2024 and N/A for FY 2025.

Per the news wire, six items were published recently, all labeled YELLOW and classified as MARKET WIRE. Headlines include a TradingView estimates report, an Investing.com report of a chief legal officer stock sale of $51,724, a Stock Titan report of a proposed 11,087-share sale by officer Shao-Lee Lin tied to tax withholding, an ad-hoc-news.de report referencing a B. Riley target of USD 83, a Value Research shareholding-pattern report, and a Stock Titan report describing a non-discretionary $51.7K share sale that would cover stock-grant taxes. Key risk watch items are the insider sale activity and the wide gap between the 52-week range and current price. The Butterfly Supply-Chain Graph lists no supply-chain links and no proprietary signals.

• What specific products, programs, or revenue sources generate the FY 2025 revenue of $27.5M?
• What are the trailing and forward earnings and valuation multiples, given that P/E, EV/EBITDA, and EPS are unavailable?
• What is the reported debt position for FY 2025, and how does the company fund its negative free cash flow?
• What are the terms and size of the officer share sales referenced in the news wire, and are they discretionary?
• What drove the 52-week range from $4.98 to $45.5, and what is the current analyst and institutional holder base?